Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions

Science

Volumn 298, Issue 5594, 2002, Pages 846-850

  Aarts, Michelle ^a   Liu, Yitao ^a   Liu, Lidong ^a   Besshoh, Shintaro ^a   Arundine, Mark ^a   Gurd, James W ^a   Wang, Yu Tian ^a   Salter, Michael W ^a   Tymianski, Michael ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLOGY; PROTEINS; TOXICITY;

STROKE;

BRAIN;

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; BICUCULLINE; CALCIUM 45; DANSYL CHLORIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NIMODIPINE; POLYPEPTIDE; POSTSYNAPTIC DENSITY PROTEIN 95; RECEPTOR SUBUNIT; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN LYSYLLEUCYLSERYLSERYLISOLEUCYLGLUTAMINYLALANYLASPARAGYLALANINE; TRANSACTIVATOR PROTEIN LYSYLLEUCYLSERYLSERYLISOLEUCYLGLUTAMINYLSERYLASPARAGYLVALINE; UNCLASSIFIED DRUG;

NERVOUS SYSTEM DISORDER; PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG TARGETING; EXCITATORY POSTSYNAPTIC POTENTIAL; FLUORESCENCE; IMMUNOPRECIPITATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL CULTURE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BLOCKING; STROKE;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CALCIUM; CELLS, CULTURED; CEREBRAL INFARCTION; CYCLIC GMP; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; PATCH-CLAMP TECHNIQUES; PEPTIDES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0037174635     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1072873     Document Type: Article

References (26)

1. T. Pawson, J. D. Scott, Science 278, 2075 (1997).
2. M. Sheng, Proc. Natl. Acad. Sci. U.S.A. 98, 7058 (2001).
3. H. C. Kornau, L. T. Schenker, M. B. Kennedy, P. H. Seeburg, Science 269, 1737 (1995).
4. J. E. Brenman et al., Cell 84, 757 (1996).
5. V. L. Dawson, T. M. Dawson, E. D. London, D. S. Bredt, S. H. Snyder, Proc. Natl. Acad. Sci. U.S.A. 88, 6368 (1991).
6. M. Migaud et al., Nature 396, 433 (1998).
7. R. Sattler et al., Science 284, 1845 (1999).
8. R. P. Simon, J. H. Swan, B. S. Meldrum, Science 226, 850 (1984).
9. A. S. Fix et al., Exp. Neurol. 123, 204 (1993).
10. S. M. Davis et al., Stroke 31, 347 (2000).
11. G. F. Morris et al., J. Neurosurg. 91, 737 (1999).
12. S. R. Schwarze, A. Ho, A. Vocero-Akbani, S. F. Dowdy, Science 285, 1569 (1999).
13. See supporting data on Science Online.
14. D. A. Mann, A. D. Frankel, EMBO J. 10, 1733 (1991).
15. 2+).
16. i before and after Tat-NR2B9c application were 1.03 ± 0.03 and 0.99 ± 0.04, respectively (n = 11 neurons).
17. R. Sattler, M. P. Charlton, M. Hafner, M. Tymianski, J. Neurochem. 71, 2349 (1998).
18. R. Sattler, Z. Xiong, W. Y. Lu, J. F. MacDonald, M. Tymianski, J. Neurosci. 20, 22 (2000).
19. S. R. Jaffrey, S. H. Snyder, Annu. Rev. Cell Dev. Biol. 11, 417 (1995).
20. Tat-NR2B9c-dansyl fluorescence was visualized in all other brain areas examined (hippocampus, striatum).
21. Tat-NR2B9c-dansyl fluorescence was detectable in brain vessels and all brain regions examined in 250-g Sprague-Dawley rats 1 hour after intravenous injection (3 nmol/g).
22. E. Z. Longa, P. R. Weinstein, S. Carlson, R. Cummins, Stroke 20, 84 (1989).
23. L. Belayev, O. F. Alonso, R. Busto, W. Zhao, M. D. Ginsberg, Stroke 27, 1616 (1996).
24. J. B. Bederson et al., Stroke 17, 472 (1986).
25. M. De Ryck, J. van Reempts, M. Borgers, A. Wauquier, P. A. Janssen, Stroke 20, 1383 (1989).
26. Supported by NIH grant NS 39060 (M.T.) and the Canadian Stroke Network (M.T., M.W.S., Y.T.W., J.G.). M.A. is a fellow of the Ontario Heart and Stroke Foundation. M.T. is a Canadian Institutes of Health Research Clinician-Scientist. Y.T.W. is the holder of the Heart Stroke Foundation of British Columbia and Yukon Chair in Stroke Research at the University of British Columbia. We thank J. F. MacDonald, L.-Y. Wang, M. Goldberg, and J. MacManus for a critical review of the manuscript, and L. Teves and Y. Li for technical assistance.